Type 1 Diabetes Leukopak

High-Yield LeukoCore Type 1 Diabetes Leukopak for Autoimmune Immunology Research

LeukoCore Type 1 Diabetes Leukopak biospecimens are collected from IRB-consented donors clinically diagnosed with type 1 diabetes (T1D) through IRB-approved apheresis procedures. Each leukopak contains large quantities of peripheral blood mononuclear cells (PBMCs), making it suited to studies that require high input cell numbers.

Why a Leukopak for Type 1 Diabetes Research

T1D is a T cell–mediated autoimmune disease in which cytotoxic lymphocytes destroy insulin-producing pancreatic beta cells. The central experimental problem is that the cells responsible are extremely rare in circulation, and a standard blood draw simply does not contain enough of them. A leukopak solves the numbers problem.

• Autoreactive T cells are rare — CD8 T cells recognising beta-cell antigens such as preproinsulin circulate at very low frequency, so tetramer or multimer-based detection and functional assays require the cell numbers only apheresis provides
• Regulatory T cell isolation at scale — defective regulatory T cell control of autoreactive responses is a core feature of T1D, and Treg purification for phenotyping, suppression assays, or expansion feasibility work is yield-limited
• HLA class II restriction shapes the response — T1D risk is strongly associated with HLA-DR and HLA-DQ haplotypes, and antigen-specific work depends on matching donor HLA type to the reagents used
• Antigen-specific readouts need replicates — low-frequency responses require large-input, multi-replicate assay designs to achieve statistical confidence, which single-tube draws cannot support
• Cell therapy and tolerance-induction feasibility — engineered regulatory T cell and antigen-specific tolerance approaches are assessed for manufacturing feasibility at scales only leukopaks reach
• One donor, many assays — a single apheresis collection allows immunophenotyping, functional assays, and multi-omics on the same donor material, eliminating inter-donor variability as a confounder

Donor Stratification Available

• Disease duration — new-onset within the first year versus long-standing disease
• Islet autoantibody profile — GAD65, IA-2, ZnT8, and insulin autoantibody status where measured
• Residual beta-cell function — C-peptide detectable versus undetectable where measured
• HLA type — HLA-A typing included; extended class II typing available on request
• Glycaemic control and treatment modality — HbA1c where recorded; injection, pump, or automated insulin delivery
• Age at onset — paediatric versus adult onset; coexisting autoimmune disease where documented
• Matched healthy controls available — demographically matched healthy donor leukopaks

Product Features

• Research Use Only (RUO) human leukopaks
• Clinically confirmed T1D donors
• High cell yield for large-scale studies
• Processed and shipped within 24 hours of collection
• Fresh or cryopreserved options available
• Cell yield and viability reported per lot
• IRB-approved and ethically sourced
• Infectious disease testing
• HLA-A typing
• Screen donors with LeukoLot™

De-identified Donor Data

• Verified T1D diagnosis from healthcare providers
• Donor demographics: age, sex assigned at birth, race/ethnicity
• Self-reported medication history and allergies
• Relevant clinical data including age at onset and disease duration (if available)

Applications

• Antigen-specific autoreactive T cell detection by tetramer or multimer staining
• Regulatory T cell isolation, phenotyping, and suppression assays
• Immune cell characterisation and deep immunophenotyping in T1D
• Cell-based assays, cytokine profiling, and functional readouts at scale
• Multi-omics studies including single-cell and TCR repertoire sequencing
• HLA-restricted antigen presentation research
• Cell therapy and tolerance-induction feasibility studies
• Therapeutic development, screening, and mechanism-of-action work

Other Type 1 Diabetes Specimen Types

Matched material from the same T1D donor pool is available as type 1 diabetes serum, plasma, whole blood, and PBMC. Isolated subsets are available as CD4+ T cells, CD8+ T cells, and CD19+ B cells.

Compliance and Quality Assurance

• Collected under IRB oversight with donor e-consent (21 CFR Part 11 compliant)
• HIPAA-compliant handling of donor information
• Rigorous donor screening and documentation

Ordering & Customization

Type 1 Diabetes Leukopak samples are available fresh or cryopreserved. For pricing, or to check current availability across our full leukopak inventory, visit our human leukopak page to browse other disease-state options and live stock status. For international shipping or regulatory documentation, please contact learnmore@sanguinebio.com to confirm regional compliance and shipping availability.